JOHN FERNANDES, MD., Director & Professor, Institute of Psychiatry & Human Behaviour, Goa.
Indian J Psychiatry. 1999 Jul;41(3):242-8.
In an open trial, patients with ICD-10 diagnosis of acute functional psychoses were administered injection Zuclopenthixol acetate (Acuphase) in the initial phase. Patients were rated with CGI, BPRS -24 item and UKU side effect rating scale at baseJine, 24 hours and 72 hours. Of the 120 patients recruited, 119 finished this part of the trial. The most common side effect was sedation, which was preferable as most of the patients were in the acute state. The issues concerning less dosing efficacy and the rapid onset of antipsychotic activity are discussed.Patients who had been administered zuclopenthixol acetate in the acute phase were maintained with injection zuclopenthixol decanoate (depot) starting at 72 hours over the baseline. Patients were assessed at 72 hours, one week, 2 weeks, 3 vseeks, 4 weeks and 8 weeks using the same instruments. The issues concerning the dosage and therapeutic efficacy are discussed.
在一项开放性试验中，符合 ICD-10 急性功能性精神病诊断的患者在急性期接受了齐拉西酮乙酸酯（Acuphase）注射治疗。患者在基线、24 小时和 72 小时时使用 CGI、BPRS-24 项和 UKU 副作用评定量表进行评分。在招募的 120 名患者中，119 名完成了这部分试验。最常见的副作用是镇静，这是可取的，因为大多数患者处于急性期。讨论了关于剂量效果降低和抗精神病作用迅速出现的问题。在急性期接受齐拉西酮乙酸酯治疗的患者，从基线开始在 72 小时后使用齐拉西酮癸酸酯（长效）进行注射维持治疗。患者在 72 小时、1 周、2 周、3 周、4 周和 8 周时使用相同的工具进行评估。讨论了剂量和治疗效果的问题。
